Hori­zon Ther­a­peu­tics in takeover talks with Am­gen, J&J, Sanofi as po­ten­tial buy­ers

Am­gen, J&J’s Janssen and Sanofi are all in talks to ac­quire Hori­zon Ther­a­peu­tics, the rare dis­ease biotech dis­closed late Tues­day.

Hori­zon con­firmed “high­ly pre­lim­i­nary dis­cus­sions” with those com­pa­nies re­gard­ing a po­ten­tial buy­out of­fer af­ter the Wall Street Jour­nal re­port­ed takeover in­ter­est.

Al­though the com­pa­ny — which com­mands a mar­ket cap of close to $18 bil­lion — em­pha­sized that “there can be no cer­tain­ty that any of­fer will be made for the Com­pa­ny,” shares $HZNP still surged 31% in af­ter-hours trad­ing to near $103, bring­ing it to the point where it start­ed the year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER